Unibest

Pharmaceutical intermediates

Afatinib Intermediates

1 pharmaceutical intermediate for Afatinib. Indication: Carcinoma, Non-Small-Cell Lung.

提交项目All intermediates

About Afatinib

Originator
Boehringer Ingelheim
Indication
Carcinoma, Non-Small-Cell Lung
Approved Date
07/12/2013
DS/DP
01/13/2026

Available intermediates

1 intermediate currently listed for Afatinib. Request specifications, documentation or a quotation for any item below.

Afatinib intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
N-(3-chloro-4-fluorophenyl)-7-fluoro-6-nitroquinazolin-4-aMine162012-67-1//

Other programs under A

AbemaciclibAbrocitinibAcalabrutinibAdagrasibAfoxolanerAlectinib HydrochlorideAlfacalcidolAlogliptin/ Trelagliptin

Building toward Afatinib?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →